Employees: 11-50
Total raised: $29.5M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Mayo Clini... | ventures.m... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.05.2022 | Series B | $29.5M | - |
Mentions in press and media 5
| Date | Title | Description |
| 12.11.2024 | Учёная вылечила рак с помощью вирусов, которые сама вырастила в лаборатории | Вирусолог Беата Халаши утверждает, что самостоятельное лечение сработало и принесло положительные результаты — но исследователи предупреждают, что такое лечение не стоит повторять. Вирус кори, может атаковать раковые клетки. Источник: Eye O... |
| 18.05.2022 | Vyriad Raises $29.5M in Series B Funding | Vyriad, a Rochester, MN-based clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, raised $29.5M in Series B funding. The round was led by Mr. Harry Stine of Stine Seed Farms, Inc. with... |
| 17.05.2022 | Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur | ROCHESTER, MINNESOTA, UNITED STATES, May 17, 2022 /EINPresswire.com/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by... |
| 17.05.2022 | Minnesota biotech firm Vyriad raises $29.5 million for cancer-fighting viruses | - |
| 05.04.2022 | Oral Vaccine Boosts COVID Immunity | ROCHESTER, MINNESOTA, US, April 5, 2022 /EINPresswire.com/ -- Oral Vaccine Boosts COVID Immunity Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced res... |